Edgewise Current Ratio from 2010 to 2025

EWTX Stock  USD 26.26  0.46  1.72%   
Edgewise Therapeutics Current Ratio yearly trend continues to be fairly stable with very little volatility. Current Ratio is likely to outpace its year average in 2025. Current Ratio is a liquidity ratio that measures a company's ability to pay short-term obligations or those due within one year. It compares a firm's current assets to its current liabilities. View All Fundamentals
 
Current Ratio  
First Reported
2010-12-31
Previous Quarter
22.42
Current Value
26.07
Quarterly Volatility
2.71743245
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Edgewise Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Edgewise Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 17.1 M, Interest Income of 17.1 M or Depreciation And Amortization of 2.1 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 2.07. Edgewise financial statements analysis is a perfect complement when working with Edgewise Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Edgewise Therapeutics Correlation against competitors.
For more information on how to buy Edgewise Stock please use our How to Invest in Edgewise Therapeutics guide.

Latest Edgewise Therapeutics' Current Ratio Growth Pattern

Below is the plot of the Current Ratio of Edgewise Therapeutics over the last few years. It is a liquidity ratio that measures a company's ability to pay short-term obligations or those due within one year. It compares a firm's current assets to its current liabilities. Edgewise Therapeutics' Current Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Edgewise Therapeutics' overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported 27.49 X10 Years Trend
Slightly volatile
   Current Ratio   
       Timeline  

Edgewise Current Ratio Regression Statistics

Arithmetic Mean22.38
Geometric Mean22.25
Coefficient Of Variation12.14
Mean Deviation1.94
Median21.24
Standard Deviation2.72
Sample Variance7.38
Range10.3606
R-Value0.39
Mean Square Error6.73
R-Squared0.15
Significance0.14
Slope0.22
Total Sum of Squares110.77

Edgewise Current Ratio History

2025 26.07
2024 22.42
2023 19.5
2022 21.22
2021 26.69
2020 29.86

About Edgewise Therapeutics Financial Statements

Edgewise Therapeutics investors use historical fundamental indicators, such as Edgewise Therapeutics' Current Ratio, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Edgewise Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Ratio 22.42  26.07 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Edgewise Stock Analysis

When running Edgewise Therapeutics' price analysis, check to measure Edgewise Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Edgewise Therapeutics is operating at the current time. Most of Edgewise Therapeutics' value examination focuses on studying past and present price action to predict the probability of Edgewise Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Edgewise Therapeutics' price. Additionally, you may evaluate how the addition of Edgewise Therapeutics to your portfolios can decrease your overall portfolio volatility.